Kent Imaging Inc. Receives FDA 510(k) Clearance on SnapshotNIR V3.0

CALGARY, January 6, 2021 /EIN Presswire/ - Kent Imaging announced today the FDA 510(k) clearance for SnapshotNIR V3.0(KD204) – now available for shipping. This upgrade provides significant feature enhancements to the imaging technology that advances tissue assessment in acute and chronic wounds. The multitude of advancements include the ability to image most skin tones (overcoming the melanin barrier), linear and surface area wound measurements, easy report generation with image comparisons, and enhanced patient file management, to name a few.

SnapshotNIR utilizes near-infrared light to determine tissue oxygen saturation (StO2), which is a key indicator of tissue health. Ideal for microcirculation assessment, it conveys a comprehensive picture of the healing capacity of wounds or surgical tissue. This critical information is used to support clinical judgment in choosing, evaluating, and tracking treatment and surgical options throughout the care continuum.

“We are excited to release this enhanced version of SnapshotNIR as part of Kent’s dedication to bringing innovation to this critical market. Robust features asked for by front-line wound care specialists and reconstructive surgeons have been incorporated, delivering a product that can easily track and document wound healing progress and support therapeutic decisions,” noted Pierre Lemire, CEO. “SnapshotNIR V3.0 continues to support the goal of delivering on solutions that aid wound care and surgical specialists in improving patient outcomes and reducing complications.”